skip to the content

Clinical Trials

Peritoneal Cancer Study

GOG 0213: A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab (NSC# 704865, IND# 7921) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurren

Protocol ID

08-150

Protocol Description

This study is being done to find a more effective treatment for ovarian, fallopian tube or peritoneal primary cancer that has come back after a patient's original treatment. One purpose of this study is to compare the combination of carboplatin, paclitaxel and bevacizumab to the standard combination of carboplatin and paclitaxel alone.

Effectiveness of treatment will be measured in terms of survival, time without evidence of cancer growth and quality of life (wellness and physical functioning).

A second purpose of this study is to determine if a second surgery to remove tumors followed by chemotherapy can increase the time that patients remain disease free.

Eligibility Criteria

Women whose ovarian, fallopian tube or peritoneal primary cancer has returned after original treatment

Primary Investigator(s)

  • Veena John, MD

Contact Information

Laureen Thumser, RN
(516) 734-8979
lthumser@nshs.edu

Last Update

March 26, 2010
top
  • Share this Page
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Cancer:
top
top